menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Breaking Down Barriers for PAH Patient Risk Assessment Through EHR Systems

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Unsure how to implement the REVEAL 2.0 and REVEAL Lite 2 risk assessment calculators into your EHR system? Explore a resource that can help.

  • Sponsored by

  • Overview

    According to the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines, regular risk assessments should be conducted in patients with pulmonary arterial hypertension (PAH).1 The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 2.0 and REVEAL Lite 2, are two risk assessment tools available to clinicians.2,3 While several barriers to their widespread implementation into EHR systems exist,4 Janssen is here to help with the EHR Build Guide. Learn more about this educational resource for healthcare professionals with Dr. Abhijit Raval and patient coordinator Ms. Kelly Dickson.

    References:

    1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022
    2. Benza RL, Kanwar MK, Raina A, et al. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. CHEST. 2021;159(1):337-346. doi:10.1016/j.chest.2020.08.2069
    3. Benza RL, Lohmueller LC, Kraisangka J, Kanwar M. Risk assessment in pulmonary arterial hypertension patients: the long and short of it. Advances in Pulmonary Hypertension. 2018;16(3):125-135.
    4. Wilson M, Keeley J, Kingman M, Wang J, Rogers F. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulm Circ. 2020;10:2045894020950186

    © 2023 Actelion Pharmaceuticals US, Inc. cp-255991v2 10/23 

Schedule29 Feb 2024